Vas Narasimhan, the chief executive of pharmaceutical giant Novartis, has been appointed to the board of leading artificial intelligence firm Anthropic. This high-profile addition is viewed as a significant strategic move for Anthropic as it reportedly inches closer to a potential public listing.
A Physician-Scientist's Expertise for AI Governance
Narasimhan, a physician-scientist by training, brings a unique blend of experience in science, regulation, and scaling complex technologies. His career, including an MD from Harvard Medical School and a Master’s in Public Policy from Harvard Kennedy School, has deeply focused on navigating highly regulated environments. Before leading Novartis, he worked extensively in global health programs addressing critical diseases across India, Africa, and South America.
At Novartis, Narasimhan oversaw the development and approval of over 35 novel medicines, demonstrating a strong track record in one of the world’s most tightly regulated industries. This background is precisely what Anthropic is leveraging to build credibility around the safe and responsible deployment of powerful AI systems.
“Getting powerful new technology to people safely and at scale is what we think about every day,” Anthropic President Daniela Amodei stated, highlighting the parallels between pharmaceutical drug development and the responsible scaling of AI.
As a public benefit corporation, Anthropic’s appointment of Narasimhan also reinforces its governance structure. The company’s independent Long-Term Benefit Trust, designed to balance financial returns with a broader public mission, now holds significant influence over the board, emphasizing a deliberate commitment to accountability.
Healthcare at the Core of AI Innovation
Narasimhan’s entry aligns with Anthropic’s sharpening focus on healthcare and life sciences, sectors where AI is beginning to demonstrate substantial commercial and societal impact. The company has already forged partnerships with major drugmakers, including Eli Lilly, Novo Nordisk, and Genmab, to explore how AI can accelerate drug development timelines and enhance patient outcomes.
Building a Board for Public Markets
Anthropic has been strategically reshaping its board in recent months, with Narasimhan’s appointment following the earlier addition of Chris Liddell. Liddell, who previously served as CFO at Microsoft and deputy White House chief of staff, also brings extensive experience in business and government.
For companies approaching public markets, the composition of their board is critical in shaping investor confidence. It signals how a firm plans to manage risk, navigate complex regulatory landscapes, and scale responsibly, particularly in rapidly evolving and scrutinized sectors like artificial intelligence. Narasimhan's pharmaceutical background, characterized by stringent safety protocols, compliance, and lengthy development cycles, offers a valuable framework for AI companies seeking to establish trust and ensure sustainable growth.